{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T20:07:04Z","timestamp":1772136424525,"version":"3.50.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":26,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-32031-9","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T13:47:25Z","timestamp":1766584045000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Focused ultrasound-mediated drug delivery of bevacizumab in treating NF2-related schwannomatosis in an animal model"],"prefix":"10.1038","volume":"16","author":[{"given":"Jennifer L.","family":"Spiegel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"De Maio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manita V.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omer J.","family":"Ungar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolyn","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tra","family":"Truong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yumai","family":"Situ","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. Wade","family":"Clapp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon J.","family":"Conway","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph M.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent Y. W.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kullervo","family":"Hynynen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meaghan A.","family":"O\u2019Reilly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trung N.","family":"Le","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,24]]},"reference":[{"key":"32031_CR1","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1136\/jmg.29.12.841","volume":"29","author":"DG Evans","year":"1992","unstructured":"Evans, D. G. et al. A genetic study of type 2 neurofibromatosis in the United Kingdom. I. Prevalence, mutation rate, fitness, and confirmation of maternal transmission effect on severity. J. Med. Genet. 29, 841\u2013846. https:\/\/doi.org\/10.1136\/jmg.29.12.841 (1992).","journal-title":"J. Med. Genet."},{"key":"32031_CR2","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1097\/00129492-200501000-00016","volume":"26","author":"DG Evans","year":"2005","unstructured":"Evans, D. G. et al. Incidence of vestibular schwannoma and neurofibromatosis 2 in the North West of England over a 10-year period: higher incidence than previously thought. Otol. Neurotol. 26, 93\u201397. https:\/\/doi.org\/10.1097\/00129492-200501000-00016 (2005).","journal-title":"Otol. Neurotol."},{"key":"32031_CR3","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1002\/ajmg.a.34359","volume":"158A","author":"JO Blakeley","year":"2012","unstructured":"Blakeley, J. O. et al. Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2. Am. J. Med. Genet. A 158A, 24\u201341. https:\/\/doi.org\/10.1002\/ajmg.a.34359 (2012).","journal-title":"Am. J. Med. Genet. A"},{"key":"32031_CR4","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1136\/jmg.2005.036319","volume":"43","author":"DG Evans","year":"2006","unstructured":"Evans, D. G., Birch, J. M., Ramsden, R. T., Sharif, S. & Baser, M. E. Malignant transformation and new primary tumours after therapeutic radiation for benign disease: substantial risks in certain tumour prone syndromes. J. Med. Genet. 43, 289\u2013294. https:\/\/doi.org\/10.1136\/jmg.2005.036319 (2006).","journal-title":"J. Med. Genet."},{"key":"32031_CR5","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s11060-021-03910-8","volume":"156","author":"U Tosi","year":"2022","unstructured":"Tosi, U. et al. Stereotactic radiosurgery for vestibular schwannomas in neurofibromatosis type 2 patients: a systematic review and meta-analysis. J. Neurooncol. 156, 431\u2013441. https:\/\/doi.org\/10.1007\/s11060-021-03910-8 (2022).","journal-title":"J. Neurooncol."},{"key":"32031_CR6","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1177\/0194599820954144","volume":"164","author":"C Sobieski","year":"2021","unstructured":"Sobieski, C. et al. Facial nerve outcomes after vestibular schwannoma microsurgical resection in neurofibromatosis type 2. Otolaryngol. Head Neck Surg. 164, 850\u2013858. https:\/\/doi.org\/10.1177\/0194599820954144 (2021).","journal-title":"Otolaryngol. Head Neck Surg."},{"key":"32031_CR7","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1097\/MAO.0000000000004442","volume":"46","author":"RJT Fujiwara","year":"2025","unstructured":"Fujiwara, R. J. T., Shi, J. J., Tan, D., Sakano, H. & Kutz, J. W. Increased costs and complication rates in vestibular schwannoma resections for neurofibromatosis type 2. Otol. Neurotol. 46, 446\u2013452. https:\/\/doi.org\/10.1097\/MAO.0000000000004442 (2025).","journal-title":"Otol. Neurotol."},{"key":"32031_CR8","doi-asserted-by":"publisher","first-page":"e590","DOI":"10.1212\/WNL.0000000000007898","volume":"93","author":"T Godel","year":"2019","unstructured":"Godel, T. et al. Peripheral nervous system alterations in infant and adult neurofibromatosis type 2. Neurology 93, e590\u2013e598. https:\/\/doi.org\/10.1212\/WNL.0000000000007898 (2019).","journal-title":"Neurology"},{"key":"32031_CR9","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s00062-021-01102-5","volume":"32","author":"T Godel","year":"2022","unstructured":"Godel, T. et al. Long-term follow-up and histological correlation of peripheral nervous system alterations in neurofibromatosis type 2. Clin. Neuroradiol. 32, 277\u2013285. https:\/\/doi.org\/10.1007\/s00062-021-01102-5 (2022).","journal-title":"Clin. Neuroradiol."},{"key":"32031_CR10","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1080\/00016480310005101","volume":"123","author":"J Brieger","year":"2003","unstructured":"Brieger, J., Bedavanija, A., Lehr, H. A., Maurer, J. & Mann, W. J. Expression of angiogenic growth factors in acoustic neurinoma. Acta Otolaryngol. 123, 1040\u20131045. https:\/\/doi.org\/10.1080\/00016480310005101 (2003).","journal-title":"Acta Otolaryngol."},{"key":"32031_CR11","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1097\/00005537-200312000-00014","volume":"113","author":"P Caye-Thomasen","year":"2003","unstructured":"Caye-Thomasen, P., Baandrup, L., Jacobsen, G. K., Thomsen, J. & Stangerup, S. E. Immunohistochemical demonstration of vascular endothelial growth factor in vestibular schwannomas correlates to tumor growth rate. Laryngoscope 113, 2129\u20132134. https:\/\/doi.org\/10.1097\/00005537-200312000-00014 (2003).","journal-title":"Laryngoscope"},{"key":"32031_CR12","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/00129492-200501000-00017","volume":"26","author":"P Caye-Thomasen","year":"2005","unstructured":"Caye-Thomasen, P. et al. VEGF and VEGF receptor-1 concentration in vestibular schwannoma homogenates correlates to tumor growth rate. Otol. Neurotol. 26, 98\u2013101. https:\/\/doi.org\/10.1097\/00129492-200501000-00017 (2005).","journal-title":"Otol. Neurotol."},{"key":"32031_CR13","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1097\/CCO.0000000000000579","volume":"31","author":"D Halliday","year":"2019","unstructured":"Halliday, D., Parry, A. & Evans, D. G. Neurofibromatosis type 2 and related disorders. Curr. Opin. Oncol. 31, 562\u2013567. https:\/\/doi.org\/10.1097\/CCO.0000000000000579 (2019).","journal-title":"Curr. Opin. Oncol."},{"key":"32031_CR14","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1080\/14737175.2018.1399795","volume":"18","author":"J Halliday","year":"2018","unstructured":"Halliday, J., Rutherford, S. A., McCabe, M. G. & Evans, D. G. An update on the diagnosis and treatment of vestibular schwannoma. Expert Rev. Neurother. 18, 29\u201339. https:\/\/doi.org\/10.1080\/14737175.2018.1399795 (2018).","journal-title":"Expert Rev. Neurother."},{"key":"32031_CR15","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1111\/coa.12882","volume":"42","author":"SKW Lloyd","year":"2017","unstructured":"Lloyd, S. K. W. et al. Hearing optimisation in neurofibromatosis type 2: A systematic review. Clin. Otolaryngol. 42, 1329\u20131337. https:\/\/doi.org\/10.1111\/coa.12882 (2017).","journal-title":"Clin. Otolaryngol."},{"key":"32031_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13237488","author":"M Screnci","year":"2024","unstructured":"Screnci, M. et al. Bevacizumab for vestibular schwannomas in neurofibromatosis type 2: a systematic review of tumor control and hearing preservation. J. Clin. Med. https:\/\/doi.org\/10.3390\/jcm13237488 (2024).","journal-title":"J. Clin. Med."},{"key":"32031_CR17","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1007\/s00280-014-2456-2","volume":"73","author":"KM Slusarz","year":"2014","unstructured":"Slusarz, K. M., Merker, V. L., Muzikansky, A., Francis, S. A. & Plotkin, S. R. Long-term toxicity of bevacizumab therapy in neurofibromatosis 2 patients. Cancer Chemother. Pharmacol. 73, 1197\u20131204. https:\/\/doi.org\/10.1007\/s00280-014-2456-2 (2014).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"32031_CR18","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1158\/1078-0432.CCR-06-2854","volume":"13","author":"JF Deeken","year":"2007","unstructured":"Deeken, J. F. & Loscher, W. The blood-brain barrier and cancer: transporters, treatment, and Trojan horses. Clin. Cancer Res. 13, 1663\u20131674. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-2854 (2007).","journal-title":"Clin. Cancer Res."},{"key":"32031_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drup.2015.02.002","volume":"19","author":"O van Tellingen","year":"2015","unstructured":"van Tellingen, O. et al. Overcoming the blood-brain tumor barrier for effective glioblastoma treatment. Drug Resist. Updat. 19, 1\u201312. https:\/\/doi.org\/10.1016\/j.drup.2015.02.002 (2015).","journal-title":"Drug Resist. Updat."},{"key":"32031_CR20","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/neuonc\/nov164","volume":"18","author":"RK Oberoi","year":"2016","unstructured":"Oberoi, R. K. et al. Strategies to improve delivery of anticancer drugs across the blood-brain barrier to treat glioblastoma. Neuro Oncol. 18, 27\u201336. https:\/\/doi.org\/10.1093\/neuonc\/nov164 (2016).","journal-title":"Neuro Oncol."},{"key":"32031_CR21","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1148\/radiol.2016152444","volume":"281","author":"HL Liu","year":"2016","unstructured":"Liu, H. L. et al. Focused ultrasound enhances central nervous system delivery of bevacizumab for malignant glioma treatment. Radiology 281, 99\u2013108. https:\/\/doi.org\/10.1148\/radiol.2016152444 (2016).","journal-title":"Radiology"},{"key":"32031_CR22","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/j.ultrasmedbio.2007.12.015","volume":"34","author":"N Sheikov","year":"2008","unstructured":"Sheikov, N., McDannold, N., Sharma, S. & Hynynen, K. Effect of focused ultrasound applied with an ultrasound contrast agent on the tight junctional integrity of the brain microvascular endothelium. Ultrasound Med. Biol. 34, 1093\u20131104. https:\/\/doi.org\/10.1016\/j.ultrasmedbio.2007.12.015 (2008).","journal-title":"Ultrasound Med. Biol."},{"key":"32031_CR23","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/j.ultrasmedbio.2006.05.015","volume":"32","author":"N Sheikov","year":"2006","unstructured":"Sheikov, N. et al. Brain arterioles show more active vesicular transport of blood-borne tracer molecules than capillaries and venules after focused ultrasound-evoked opening of the blood-brain barrier. Ultrasound Med. Biol. 32, 1399\u20131409. https:\/\/doi.org\/10.1016\/j.ultrasmedbio.2006.05.015 (2006).","journal-title":"Ultrasound Med. Biol."},{"key":"32031_CR24","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1586\/14737175.2015.1028369","volume":"15","author":"A Burgess","year":"2015","unstructured":"Burgess, A., Shah, K., Hough, O. & Hynynen, K. Focused ultrasound-mediated drug delivery through the blood-brain barrier. Expert Rev. Neurother. 15, 477\u2013491. https:\/\/doi.org\/10.1586\/14737175.2015.1028369 (2015).","journal-title":"Expert Rev. Neurother."},{"key":"32031_CR25","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/j.ultrasmedbio.2004.04.010","volume":"30","author":"N Sheikov","year":"2004","unstructured":"Sheikov, N., McDannold, N., Vykhodtseva, N., Jolesz, F. & Hynynen, K. Cellular mechanisms of the blood-brain barrier opening induced by ultrasound in presence of microbubbles. Ultrasound Med. Biol. 30, 979\u2013989. https:\/\/doi.org\/10.1016\/j.ultrasmedbio.2004.04.010 (2004).","journal-title":"Ultrasound Med. Biol."},{"key":"32031_CR26","doi-asserted-by":"publisher","first-page":"343re342","DOI":"10.1126\/scitranslmed.aaf6086","volume":"8","author":"A Carpentier","year":"2016","unstructured":"Carpentier, A. et al. Clinical trial of blood-brain barrier disruption by pulsed ultrasound. Sci. Transl. Med. 8, 343re342. https:\/\/doi.org\/10.1126\/scitranslmed.aaf6086 (2016).","journal-title":"Sci. Transl. Med."},{"key":"32031_CR27","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/S1470-2045(23)00112-2","volume":"24","author":"AM Sonabend","year":"2023","unstructured":"Sonabend, A. M. et al. Repeated blood-brain barrier opening with an implantable ultrasound device for delivery of albumin-bound paclitaxel in patients with recurrent glioblastoma: a phase 1 trial. Lancet Oncol. 24, 509\u2013522. https:\/\/doi.org\/10.1016\/S1470-2045(23)00112-2 (2023).","journal-title":"Lancet Oncol."},{"key":"32031_CR28","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.82869","volume":"17","author":"J Jurgaitis","year":"2025","unstructured":"Jurgaitis, J., Mickeviciute, K. & Jablonskiene, V. Overcoming the blood-brain barrier: focused ultrasound in glioblastoma treatment. Cureus 17, e82869. https:\/\/doi.org\/10.7759\/cureus.82869 (2025).","journal-title":"Cureus"},{"key":"32031_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2025.113631","volume":"381","author":"A De Maio","year":"2025","unstructured":"De Maio, A. et al. Evaluation of focused ultrasound modulation of the blood-brain barrier in gray and white matter. J. Control Release 381, 113631. https:\/\/doi.org\/10.1016\/j.jconrel.2025.113631 (2025).","journal-title":"J. Control Release"},{"key":"32031_CR30","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abd0772","author":"KT Chen","year":"2021","unstructured":"Chen, K. T. et al. Neuronavigation-guided focused ultrasound for transcranial blood-brain barrier opening and immunostimulation in brain tumors. Sci. Adv. https:\/\/doi.org\/10.1126\/sciadv.abd0772 (2021).","journal-title":"Sci. Adv."},{"key":"32031_CR31","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1093\/neuonc\/noab057","volume":"23","author":"Y Meng","year":"2021","unstructured":"Meng, Y. et al. MR-guided focused ultrasound liquid biopsy enriches circulating biomarkers in patients with brain tumors. Neuro Oncol. 23, 1789\u20131797. https:\/\/doi.org\/10.1093\/neuonc\/noab057 (2021).","journal-title":"Neuro Oncol."},{"key":"32031_CR32","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1038\/s41467-024-45818-7","volume":"15","author":"A Carpentier","year":"2024","unstructured":"Carpentier, A. et al. Repeated blood-brain barrier opening with a nine-emitter implantable ultrasound device in combination with carboplatin in recurrent glioblastoma: a phase I\/II clinical trial. Nat. Commun. 15, 1650. https:\/\/doi.org\/10.1038\/s41467-024-45818-7 (2024).","journal-title":"Nat. Commun."},{"key":"32031_CR33","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41582-020-00418-z","volume":"17","author":"Y Meng","year":"2021","unstructured":"Meng, Y., Hynynen, K. & Lipsman, N. Applications of focused ultrasound in the brain: from thermoablation to drug delivery. Nat. Rev. Neurol. 17, 7\u201322. https:\/\/doi.org\/10.1038\/s41582-020-00418-z (2021).","journal-title":"Nat. Rev. Neurol."},{"key":"32031_CR34","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.devcel.2023.01.002","volume":"58","author":"L Malong","year":"2023","unstructured":"Malong, L. et al. Characterization of the structure and control of the blood-nerve barrier identifies avenues for therapeutic delivery. Dev. Cell 58, 174-191.e178. https:\/\/doi.org\/10.1016\/j.devcel.2023.01.002 (2023).","journal-title":"Dev. Cell"},{"key":"32031_CR35","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1101\/gad.13.8.978","volume":"13","author":"M Giovannini","year":"1999","unstructured":"Giovannini, M. et al. Schwann cell hyperplasia and tumors in transgenic mice expressing a naturally occurring mutant NF2 protein. Genes Dev. 13, 978\u2013986. https:\/\/doi.org\/10.1101\/gad.13.8.978 (1999).","journal-title":"Genes Dev."},{"key":"32031_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/hmg\/ddu414","volume":"24","author":"JR Gehlhausen","year":"2015","unstructured":"Gehlhausen, J. R. et al. A murine model of neurofibromatosis type 2 that accurately phenocopies human schwannoma formation. Hum. Mol. Genet. 24, 1\u20138. https:\/\/doi.org\/10.1093\/hmg\/ddu414 (2015).","journal-title":"Hum. Mol. Genet."},{"key":"32031_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16081479","author":"JPJ Douwes","year":"2024","unstructured":"Douwes, J. P. J., Hensen, E. F., Jansen, J. C., Gelderblom, H. & Schopman, J. E. Bevacizumab treatment for patients with NF2-related schwannomatosis: a single center experience. Cancers https:\/\/doi.org\/10.3390\/cancers16081479 (2024).","journal-title":"Cancers"},{"key":"32031_CR38","doi-asserted-by":"publisher","first-page":"75","DOI":"10.2176\/nmc.oa.2019-0194","volume":"60","author":"M Fujii","year":"2020","unstructured":"Fujii, M. et al. Bevacizumab therapy of neurofibromatosis type 2 associated vestibular schwannoma in japanese patients. Neurol. Med. Chir. (Tokyo) 60, 75\u201382. https:\/\/doi.org\/10.2176\/nmc.oa.2019-0194 (2020).","journal-title":"Neurol. Med. Chir. (Tokyo)"},{"key":"32031_CR39","doi-asserted-by":"publisher","first-page":"vdad123","DOI":"10.1093\/noajnl\/vdad123","volume":"5","author":"MJ Webb","year":"2023","unstructured":"Webb, M. J. et al. Withdrawal of bevacizumab is associated with rebound growth of vestibular schwannomas in neurofibromatosis type 2-related schwannomatosis patients. Neurooncol. Adv. 5, vdad123. https:\/\/doi.org\/10.1093\/noajnl\/vdad123 (2023).","journal-title":"Neurooncol. Adv."},{"key":"32031_CR40","doi-asserted-by":"publisher","first-page":"E98","DOI":"10.1002\/lary.28998","volume":"131","author":"PC Comes","year":"2021","unstructured":"Comes, P. C. et al. Current management of large vestibular schwannomas for NF2 patients in a national reference center. Laryngoscope 131, E98\u2013E107. https:\/\/doi.org\/10.1002\/lary.28998 (2021).","journal-title":"Laryngoscope"},{"key":"32031_CR41","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s11060-010-0121-0","volume":"99","author":"RM Zuniga","year":"2010","unstructured":"Zuniga, R. M. et al. Rebound tumour progression after the cessation of bevacizumab therapy in patients with recurrent high-grade glioma. J. Neurooncol. 99, 237\u2013242. https:\/\/doi.org\/10.1007\/s11060-010-0121-0 (2010).","journal-title":"J. Neurooncol."},{"key":"32031_CR42","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1172\/JCI24612","volume":"116","author":"MR Mancuso","year":"2006","unstructured":"Mancuso, M. R. et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J. Clin. Investig. 116, 2610\u20132621. https:\/\/doi.org\/10.1172\/JCI24612 (2006).","journal-title":"J. Clin. Investig."},{"key":"32031_CR43","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1055\/s-0038-1676628","volume":"80","author":"DE Killeen","year":"2019","unstructured":"Killeen, D. E., Klesse, L., Tolisano, A. M., Hunter, J. B. & Kutz, J. W. Jr. Long-term effects of bevacizumab on vestibular schwannoma volume in neurofibromatosis type 2 patients. J. Neurol. Surg. B Skull Base 80, 540\u2013546. https:\/\/doi.org\/10.1055\/s-0038-1676628 (2019).","journal-title":"J. Neurol. Surg. B Skull Base"},{"key":"32031_CR44","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1093\/nop\/npv065","volume":"3","author":"KA Morris","year":"2016","unstructured":"Morris, K. A. et al. Bevacizumab in neurofibromatosis type 2 (NF2) related vestibular schwannomas: a nationally coordinated approach to delivery and prospective evaluation. Neurooncol. Pract. 3, 281\u2013289. https:\/\/doi.org\/10.1093\/nop\/npv065 (2016).","journal-title":"Neurooncol. Pract."},{"key":"32031_CR45","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1200\/JCO.2015.64.3817","volume":"34","author":"JO Blakeley","year":"2016","unstructured":"Blakeley, J. O. et al. Efficacy and biomarker study of bevacizumab for hearing loss resulting from neurofibromatosis type 2-associated vestibular schwannomas. J. Clin. Oncol. 34, 1669\u20131675. https:\/\/doi.org\/10.1200\/JCO.2015.64.3817 (2016).","journal-title":"J. Clin. Oncol."},{"key":"32031_CR46","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.28228","volume":"67","author":"S Renzi","year":"2020","unstructured":"Renzi, S. et al. Bevacizumab for NF2-associated vestibular schwannomas of childhood and adolescence. Pediatr. Blood Cancer 67, e28228. https:\/\/doi.org\/10.1002\/pbc.28228 (2020).","journal-title":"Pediatr. Blood Cancer"},{"key":"32031_CR47","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16010236","author":"M Pinkiewicz","year":"2024","unstructured":"Pinkiewicz, M., Pinkiewicz, M., Walecki, J., Zaczynski, A. & Zawadzki, M. Breaking barriers in neuro-oncology: a scoping literature review on invasive and non-invasive techniques for blood-brain barrier disruption. Cancers https:\/\/doi.org\/10.3390\/cancers16010236 (2024).","journal-title":"Cancers"},{"key":"32031_CR48","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41596-018-0105-7","volume":"14","author":"J Chen","year":"2019","unstructured":"Chen, J. et al. A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma. Nat. Protoc. 14, 541\u2013555. https:\/\/doi.org\/10.1038\/s41596-018-0105-7 (2019).","journal-title":"Nat. Protoc."},{"key":"32031_CR49","doi-asserted-by":"publisher","first-page":"14676","DOI":"10.1073\/pnas.1512570112","volume":"112","author":"X Gao","year":"2015","unstructured":"Gao, X. et al. Anti-VEGF treatment improves neurological function and augments radiation response in NF2 schwannoma model. Proc. Natl. Acad. Sci. USA 112, 14676\u201314681. https:\/\/doi.org\/10.1073\/pnas.1512570112 (2015).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"32031_CR50","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s11060-017-2567-9","volume":"135","author":"I Paldor","year":"2017","unstructured":"Paldor, I. et al. The efficacy of lapatinib and nilotinib in combination with radiation therapy in a model of NF2 associated peripheral schwannoma. J. Neurooncol. 135, 47\u201356. https:\/\/doi.org\/10.1007\/s11060-017-2567-9 (2017).","journal-title":"J. Neurooncol."},{"key":"32031_CR51","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1148\/radiol.11111417","volume":"263","author":"MA O'Reilly","year":"2012","unstructured":"O\u2019Reilly, M. A. & Hynynen, K. Blood\u2013brain barrier: real-time feedback-controlled focused ultrasound disruption by using an acoustic emissions-based controller. Radiology 263, 96\u2013106. https:\/\/doi.org\/10.1148\/radiol.11111417 (2012).","journal-title":"Radiology"},{"key":"32031_CR52","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1002\/mrm.1910030602","volume":"3","author":"J Hennig","year":"1986","unstructured":"Hennig, J., Nauerth, A. & Friedburg, H. RARE imaging: a fast imaging method for clinical MR. Magn. Reson. Med. 3, 823\u2013833. https:\/\/doi.org\/10.1002\/mrm.1910030602 (1986).","journal-title":"Magn. Reson. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-32031-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-32031-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-32031-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T00:07:37Z","timestamp":1769213257000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-32031-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,24]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["32031"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-32031-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7273065\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,24]]},"assertion":[{"value":"1 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All experimental procedures in this study were approved by the Animal Care Committee of the Sunnybrook Research Institute, which adheres to the Policies and Guidelines of the Canadian Council on Animal Care and meets all the requirements of the Provincial Statute of Ontario, Animals for Research Act as well as those of the Canadian Federal Health of Animals Act. The authors comply with the ARRIVE (Animal Research: Reporting of In Vivo Experiments) guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2340"}}